ArticleJournal of virology2003
Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Review
- Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic.NPJ vaccines · 2021Review
- Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.Viruses · 2021Review
- Broad and Efficient Activation of Memory CD4Frontiers in immunology · 2021Article
- High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy.International journal of molecular sciences · 2020Review
- Review
- Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.Journal of virology · 2018Article
- Contributions of CD8 T cells to the pathogenesis of mouse adenovirus type 1 respiratory infection.Virology · 2017Article
- Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Review
- Prostaglandin E2 Production and T Cell Function in Mouse Adenovirus Type 1 Infection following Allogeneic Bone Marrow Transplantation.PloS one · 2015Article
- Adenovirus infections in immunocompetent and immunocompromised patients.Clinical microbiology reviews · 2014Review
- Immunology. Immune activation with HIV vaccines.Science (New York, N.Y.) · 2014Article
- Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?.Human vaccines & immunotherapeutics · 2014Review
- Adenovirus DNA replication.Cold Spring Harbor perspectives in biology · 2013Review
- Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation.Advances in hematology · 2013Review
- Enhanced transduction of CAR-negative cells by protein IX-gene deleted adenovirus 5 vectors.Virology · 2011Article
- Immune recognition of gene transfer vectors: focus on adenovirus as a paradigm.Frontiers in immunology · 2011Article
- Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses.Gene therapy · 2010Article
- Adenoviruses in immunocompromised hosts.Clinical microbiology reviews · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenovirus (Ad)-specific T-cell responses in healthy adult donors were investigated. Ad5, inactivated by methylene blue plus visible light, induced proliferation and gamma interferon (IFN-gamma) production in peripheral blood mononuclear cells of the majority of donors. Responding T cells were CD4(+) and produced IFN-gamma upon restimulation with infectious Ad5 and Ads of different subgroups. T-cell clones showed distinct cross-reactivity patterns recognizing Ad serotypes from either one subgroup (C), two subgroups (B and C), or three subgroups (A, B, and C). This cross-reactivity of Ad-specific T cells has relevance both for Ad-based gene therapy protocols, as well as for the feasibility of T-cell-mediated adoptive immunotherapy in recipients of an allogeneic stem cell transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.